An official website of the United States government
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Trial Status: active
The goal of this clinical trial is to learn if the experimental antibody COM701 delays
the progression of ovarian cancer in participants with Relapsed Platinum Sensitive
Ovarian Cancer. It will also learn about the safety of COM701.
The main questions the trial aims to answer are:
- Does COM701, when used as a maintenance treatment, stop or slow the progression of
ovarian cancer?
- Does COM701 delay the time to needing a new anti-cancer treatment?
- What side effects do participants have when taking COM701?
Participants will:
- Visit the clinic once every 3 weeks during which the study treatment will be
administered intravenously
- Undergo various tests and procedures to monitor general health throughout the trial
including physical examinations, vital sign measurements (heart rate, blood
pressure, breathing, and body temperature), weight measurements, electrocardiography
(ECG), blood and urine tests and pregnancy tests if relevant.
- Undergo various tests and procedures to assess disease response throughout the trial
including tumor imaging by CT scans or MRI to assess the tumor, its location, and
size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh
biopsy if feasible, to evaluate tumor response to treatment and to measure levels of
tumor markers,
Inclusion Criteria
Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
Has completed at least 2 previous courses (i.e. lines) of platinum-containing therapy
For the last chemotherapy course prior to being randomized into the study, must have had a minimum of 4 cycles of a platinum containing regimen and achieved a partial or complete tumor response.
Has received prior maintenance therapy with bevacizumab or a PARP inhibitor if eligible and is not a candidate for, or has declined in writing, bevacizumab or PARP inhibitor therapy.
Have recovered from toxicities of prior chemotherapy or other therapy (to grade 1 or less, except for alopecia and neuropathy recovered to a ≤grade 2).
Exclusion Criteria
Has had 4 or more lines of cytotoxic chemotherapy in total
Is being treated with immunosuppressive doses of systemic medications, such as steroids within 2 weeks before study drug administration
Has had prior treatment with PD-1, PD-L1, anti-PVRIG, TIGIT or any other check point inhibitors
Presence of radiographic or biopsy proven liver metastases at the beginning or completion of current line of platinum-based chemotherapy.
Drainage of ascites during last 2 cycles of last chemotherapy or any time after completion of the last chemotherapy regimen.
Bowel obstruction in the 6 weeks prior to randomization.
Have known active central nervous system metastases and/or carcinomatous meningitis / leptomeningeal carcinomatosis.
Has active hepatitis B virus (HBV) or hepatitis C virus (HCV), or subjects with human immunodeficiency virus (HIV).
Has active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.
Has received a live viral vaccine within 30 days of planned start of study treatment or requiring a live vaccine during the study.
Has a history of severe allergic, anaphylactic, or other hypersensitivity reactions to a human or humanized monoclonal antibody (mAb) or allergy to any excipients in the investigational products.
Has any serious or unstable concomitant systemic disorder
Has any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the opinion of the investigator, would make the subject inappropriate for entry into the study.
Is currently participating in or have participated in a clinical study and received an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment.
Is pregnant or breastfeeding or planning to become pregnant during the period of the study.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06888921.
Locations matching your search criteria
United States
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Name Not Available
Massachusetts
Boston
Massachusetts General Hospital Cancer Center
Status: Active
Name Not Available
New York
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Name Not Available
Rochester
University of Rochester
Status: Active
Name Not Available
North Carolina
Charlotte
Carolinas Medical Center/Levine Cancer Institute
Status: Active
Name Not Available
Winston-Salem
Wake Forest University Health Sciences
Status: Active
Name Not Available
Ohio
Columbus
Ohio State University Comprehensive Cancer Center
Status: Active
Name Not Available
Virginia
Charlottesville
University of Virginia Cancer Center
Status: Active
Name Not Available
Trial CPG-01-201 is an adaptive-platform trial comprised of multiple sub-studies.
Sub-study 1 will be a parallel group, double-blind, randomized placebo-controlled trial
in which participants will be randomized in a 1:2 ratio to either placebo (a look-alike
substance that contains no drug) or COM701 treatment arms. This means that there is a 33%
chance of being placed in the group getting placebo and a 67% chance of being placed in
the group that will get the experimental COM701 antibody.
Subsequent sub-studies will evaluate COM701 in combination with other anti-cancer drugs.
